The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Open accessAbstract
Adjuvants are critical for the success of vaccines. Agonists of microbial pattern recognition receptors (PRRs) are promising new adjuvant candidates. A mechanism through which adjuvants enhance immune responses is to stimulate innate immunity. We studied the innate immune response in humans to synthetic double-stranded RNA (polyinosinic:polycytidylic acid [poly IC] stabilized with poly-l-lysine [poly ICLC]), an agonist for toll-like receptor (TLR) 3, and the cytosolic RNA helicase MDA-5. Transcriptional analysis of blood samples from eight volunteers, after subcutaneous administration of poly ICLC, showed up-regulation of genes involved in multiple innate immune pathways in all subjects, including interferon (IFN) and inflammasome signaling. Blocking type I IFN receptor ex vivo significantly dampened the response to poly IC. Comparative transcriptional analysis showed that several innate immune pathways were similarly induced in volunteers immunized with the highly efficacious yellow fever vaccine. Therefore, a chemically defined PRR agonist like poly ICLC can be a reliable and authentic microbial mimic for inducing innate immune responses in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,433
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Inferences, questions and possibilities in Toll-like receptor signalling
Beutler, B. (2004) · Nature · doi:10.1038/nature02761 · Cited by 1,466
Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans
Querec, T. D., Akondy, R. S., Lee, E. K., Cao, W., Nakaya, H. I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. (2009) · Nature Immunology · doi:10.1038/ni.1688 · Cited by 1,121
Le Bon, A., Schiavoni, G., D'Agostino, G., Gresser, I., Belardelli, F., & Tough, D. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00126-1 · Cited by 974
Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J., & Murali-Krishna, K. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050821 · Cited by 965
Vaccines: Correlates of Vaccine‐Induced Immunity
Plotkin, S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/589862 · Cited by 829 · cited 1×
“However, significant challenges remain to develop effective and safe vaccines against important diseases such as HIV, malaria, and tuberculosis (Plotkin, 2008; Germain, 2010).”
BackgroundImpact of Protein Kinase PKR in Cell Biology: from Antiviral to Antiproliferative Action
García, M. A., Gil, J., Ventoso, I., Guerra, S., Domingo, E., Rivas, C., & Esteban, M. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00027-06 · Cited by 818
Inflammasome recognition of influenza virus is essential for adaptive immune responses
Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R., & Iwasaki, A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081667 · Cited by 684
Longhi, M. P., Trumpfheller, C., Idoyaga, J., Caskey, M., Matos, I., Kluger, C., Salazar, A. M., Colonna, M., & Steinman, R. M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090247 · Cited by 663
Self-citationTranslating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses
Gaucher, D., Therrien, R., Kettaf, N., Angermann, B. R., Boucher, G., Filali-Mouhim, A., Moser, J. M., Mehta, R. S., Drake, D. R., Castro, E., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20082292 · Cited by 594
Self-citationOkada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.7744 · Cited by 567
Self-citationNew horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Querec, T., Bennouna, S., Alkan, S., Laouar, Y., Gorden, K., Flavell, R., Akira, S., Ahmed, R., & Pulendran, B. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051720 · Cited by 552
Unbiased Reconstruction of a Mammalian Transcriptional Network Mediating Pathogen Responses
Amit, I., Garber, M., Chevrier, N., Leite, A. P., Donner, Y., Eisenhaure, T., Guttman, M., Grenier, J. K., Li, W., Zuk, O., et al. (2009) · Science · doi:10.1126/science.1179050 · Cited by 488
Toll-Like Receptors and RNA Helicases: Two Parallel Ways to Trigger Antiviral Responses
Meylan, E., & Tschopp, J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.012 · Cited by 372
Inflammasomes: guardians of cytosolic sanctity
Lamkanfi, M., & Dixit, V. M. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00730.x · Cited by 361
Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming
Le Bon, A., Durand, V., Kamphuis, E., Thompson, C., Bulfone-Paus, S., Rossmann, C., Kalinke, U., & Tough, D. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.8.4682 · Cited by 283
Stahl-Hennig, C., Eisenblätter, M., Jasny, E., Rzehak, T., Tenner-Racz, K., Trumpfheller, C., Salazar, A. M., Überla, K., Nieto, K., Kleinschmidt, J., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000373 · Cited by 198
Self-citationDissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells
Waddell, S. J., Popper, S. J., Rubins, K., Griffiths, M. J., Brown, P. O., Levin, M., & Relman, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009753 · Cited by 148
Morse, M. A., Chapman, R., Powderly, J. D., Blackwell, K., Keler, T., Green, J., Riggs, R., He, L.-Z., Ramakrishna, V., Vitale, L. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0891 · Cited by 142
Xu, W., Santini, P. A., Matthews, A. J., Chiu, A., Plebani, A., He, B., Chen, K., & Cerutti, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.276 · Cited by 126
Regulation of inflammasome activity
Guarda, G., & So, A. K.-L. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03283.x · Cited by 112
Vaccines and the Future of Human Immunology
Germain, R. N. (2010) · Immunity · doi:10.1016/j.immuni.2010.09.014 · Cited by 106
Huang, C. C., Duffy, K. E., Mateo, L. R. S., Amegadzie, B. Y., Sarisky, R. T., & Mbow, M. (2006) · Physiological Genomics · doi:10.1152/physiolgenomics.00002.2006 · Cited by 73
The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants
Harris, J., Sharp, F. A., & Lavelle, E. C. (2010) · European Journal of Immunology · doi:10.1002/eji.200940172 · Cited by 49
Cited by
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Self-citationEmerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Self-citationTowards personalized, tumour-specific, therapeutic vaccines for cancer
Hu, Z., Ott, P. A., & Wu, C. J. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.131 · Cited by 1,067
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Metadata
- Authors
- Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., Duque-Alarcon, A., Pan, L., Nelkenbaum, A., Salazar, A. M., Schlesinger, S. J., Steinman, R. M., & Sékaly, R. P.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2011-11-07
- Volume
- 208
- Issue
- 12
- Pages
- 2357-2366
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2150944106
- Cited by
- 271
- References
- 34
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.